A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Status:
Recruiting
Trial end date:
2024-01-22
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate
the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with
Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.